EUVIMEDEUVIMED entdecken
Open Access

Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community

Jennifer R Havens, Michelle R Lofwall, April M Young, Michele Staton, Takako Schaninger, Hannah Fraser, Peter Vickerman iD, Sharon L Walsh

Journal of Viral Hepatitis · 2024

DOI: 10.1111/jvh.13933 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Viral Hepatitis, 2024. Verfasst von Jennifer R Havens und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center on Drug and Alcohol Research, Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky, USA. Hauptthemen laut MEDLINE: Rural Population, Hepatitis C, Mass Screening. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, NCI NIH HHS, Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An HCV treatment trial was initiated in September 2019 to address the opioid/hepatitis C virus (HCV) syndemic in rural Kentucky. The focus of the current analysis is on participation in diagnostic screening for the trial. Initial eligibility (≥18 years of age, county resident) was established by phone followed by in‐person HCV viremia testing. 900 rural residents met the inclusion criteria and comprised the analytic sample. Generalized linear models were specified to estimate the relative risk of non‐attendance at the in‐person visit determining HCV eligibility. Approximately one‐quarter (22.1%) of scheduled participants were no‐shows. People who inject drugs were no more likely than people not injecting drugs to be a no‐show; however, participants ≤35 years of age were significantly less likely to attend. While the median time between phone screening and scheduled in‐person screening was only 2 days, each additional day increased the odds of no‐show by 3% (95% confidence interval: 2%–3%). Finally, unknown HCV status predicted no‐show even after adjustment for age, gender, days between screenings and injection status. We found that drug injection did not predict no‐show, further justifying expanded access to HCV treatment among people who inject drugs. Those 35 years and younger were more likely to no‐show, suggesting that younger individuals may require targeted strategies for increasing testing and treatment uptake. Finally, streamlining the treatment cascade may also improve outcomes, as participants in the current study were more likely to attend if there were fewer days between phone screening and scheduled in‐person screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rural PopulationHepatitis CMass ScreeningHumansFemaleMaleAdultMiddle AgedKentuckyAppalachian RegionYoung AdultAdolescentHepacivirusAntiviral Agents

Stichwörter der Autor:innen

HCV treatmentPWIDPWUDhepatitis Crural

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Center on Drug and Alcohol Research, Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
  • Department of Epidemiology, University of Kentucky College of Public Health, Lexington, Kentucky, USA.
  • Division of Infectious Disease, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
  • Bristol Population Health Sciences Institute, Bristol Medical School, Bristol, UK.

ORCID-Profile: Peter Vickerman

Förderung

  • NIDA NIH HHS
  • NCI NIH HHS
  • Gilead Sciences
  • National Institute on Drug Abuse
  • National Cancer Institute

Zitieren

APA

Havens, J. R., Lofwall, M. R., Young, A. M., Staton, M., Schaninger, T., Fraser, H., Vickerman, P., & Walsh, S. L. (2024). Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community. Journal of Viral Hepatitis. https://doi.org/10.1111/jvh.13933

Vancouver

Havens JR, Lofwall MR, Young AM, Staton M, Schaninger T, Fraser H, et al. Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community. Journal of Viral Hepatitis. 2024. doi:10.1111/jvh.13933

BibTeX
@article{Havens2024,
  author = {Havens, Jennifer R and Lofwall, Michelle R and Young, April M and Staton, Michele and Schaninger, Takako and Fraser, Hannah and Vickerman, Peter and Walsh, Sharon L},
  title = {Predictors of engagement in screening for a hepatitis C virus (HCV) treatment trial in a rural Appalachian community},
  journal = {Journal of Viral Hepatitis},
  year = {2024},
  doi = {10.1111/jvh.13933}
}
Kostenlos starten →